Singapore-based life sciences ecosystem builder Esco Group is investing Rmb100 million ($15 million) into a new manufacturing and innovation complex in China, with the aim of serving the rapidly growing Chinese market and address unmet needs for Chinese patients.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
